Tempest Therapeutics (TPST) announced that the European Medicines Agency has granted Orphan Drug Designation to amezalpat, an oral, small molecule, selective PPAR antagonist for the treatment of patients with hepatocellular carcinoma. Earlier in the year, the FDA had granted both ODD and Fast Track Designation to amezalpat to treat patients with HCC.
The company said these three designations follow positive data across multiple key study efficacy and safety endpoints from a global, randomized Phase 1b/2 clinical study evaluating amezalpat plus standard-of-care atezolizumab and bevacizumab versus atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic HCC.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.